{"id":547118,"date":"2026-08-26T23:36:21","date_gmt":"2026-08-26T23:36:21","guid":{"rendered":"https:\/\/www.newjerseyheadlines.com\/news\/story\/547118\/reliable-supplier-of-semaglutide-cas-no-910463682-hangzhou-thinheal-pharma-tech.html"},"modified":"2026-08-26T23:36:21","modified_gmt":"2026-08-26T23:36:21","slug":"reliable-supplier-of-semaglutide-cas-no-910463682-hangzhou-thinheal-pharma-tech","status":"publish","type":"post","link":"http:\/\/www.northcarolinaheadlines.com\/news\/story\/547118\/reliable-supplier-of-semaglutide-cas-no-910463682-hangzhou-thinheal-pharma-tech.html","title":{"rendered":"Reliable Supplier of Semaglutide CAS NO: 910463-68-2 – Hangzhou Thinheal Pharma Tech"},"content":{"rendered":"

Hangzhou, Zhejiang, China – August 26, 2026 –<\/strong> In the booming global metabolic drug market, GLP\u20111 peptide drugs have become core therapeutic products for type 2 diabetes and Weight Management<\/a>. Among all GLP\u20111 analogues, Semaglutide CAS NO: 910463\u201168\u20112<\/a> stands out as a blockbuster active pharmaceutical ingredient, featuring long half\u2011life, stable blood glucose control and obvious weight\u2011loss effects. As a professional full\u2011industry\u2011chain peptide biotech enterprise founded in 2019, Hangzhou Thinheal Pharma\u2011Tech Co., Ltd. provides high\u2011purity semaglutide raw materials and one\u2011stop peptide industrialization solutions for pharmaceutical enterprises across the globe.<\/p>\n

\"3\"<\/p>\n

Basic Profile of Semaglutide CAS NO: 910463\u201168\u20112<\/p>\n

Semaglutide CAS NO: 910463\u201168\u20112 is a synthetic modified GLP\u20111 receptor agonisT Peptide<\/a> with molecular formula C\u2081\u2088\u2087H\u2082\u2089\u2081N\u2084\u2085O\u2085\u2089and molecular weight 4113.58. It appears as white to off\u2011white powder manufactured via solid\u2011phase Peptide Synthesis<\/a>, and needs to be stored at \u201120\u2103 under cold chain conditions to retain complete biological activity.<\/p>\n

Different from native GLP\u20111 which only maintains activity for several minutes inside human bodies, semaglutide is modified with fatty acid side chains at lysine sites. The structural modification enables it to bind with human albumin, extending its in\u2011vivo half\u2011life to 7 days and supporting once\u2011weekly administration. Clinically, it achieves hypoglycemic effects by stimulating glucose\u2011dependent insulin secretion, inhibiting glucagon release, delaying gastric emptying and suppressing appetite. Its applicable scenarios cover type 2 diabetes treatment, overweight and obesity intervention as well as cardiovascular risk reduction.<\/p>\n

Global market demand for semaglutide API keeps rising year after year. Industry analysis indicates that global consumption of semaglutide raw materials will reach tens of tons by 2030, bringing huge supply pressure for qualified production enterprises with standard production lines and export qualifications. The complete manufacturing system built by Hangzhou fills this practical market gap.<\/p>\n

Hangzhou Thinheal: Trusted Manufacturer of GLP\u20111 peptide API<\/p>\n

Hangzhou Thinheal Pharma\u2011Tech runs independent research laboratories and standardized GMP production bases in Hangzhou Qiantang Medicine Valley and Shaoxing coastal industrial zone. Its core team consists of industry practitioners with nearly 20\u2011year experience in peptide research and mass production, who have mastered complete synthesis, purification and quality control procedures for complex long\u2011chain peptides including semaglutide.<\/p>\n

The enterprise has achieved multi\u2011ton annual production capacity for chemically synthesized peptides, sitting among leading domestic peptide producers. For semaglutide raw materials, the company has obtained EU\u2011recognized API export certificates and finished US FDA DMF filing work, strictly following ICH, EP and USP quality specifications. Every production batch goes through rigorous HPLC purity detection, impurity profiling and bioactivity verification, keeping product purity steadily above 98.5%.<\/p>\n

\"4\"<\/p>\n

Besides bulk supply of commercial\u2011grade GLP\u20111 peptide API, the firm delivers comprehensive peptide CDMO service, covering research outsourcing, pilot\u2011scale trial production and commercial mass manufacturing. Whether clients require gram\u2011level laboratory samples, kilogram\u2011scale clinical trial batches or ton\u2011level commercial goods, technical staff will optimize synthetic routes to cut manufacturing costs and shorten project lead\u2011time, helping biotech companies accelerate new drug registration and market launch progress.<\/p>\n

Diversified Business Layout<\/p>\n

Apart from therapeutic peptide products, the company has constructed a multi\u2011dimensional product portfolio for different downstream industries.<\/p>\n

custom peptide synthesis supports custom development of linear peptides, cyclic peptides, modified long\u2011chain peptides, impurity reference substances and isotope\u2011labeled peptides. The service targets university research labs, biotech start\u2011ups and diagnostic reagent manufacturers, covering output scales from milligram to ton level to satisfy demands from each drug research phase.<\/p>\n

As for cosmetic peptide raw material, the enterprise develops multiple anti\u2011aging, brightening and anti\u2011wrinkle peptide ingredients. Representative products include acetyl hexapeptide\u20118, palmitoyl tripeptide\u20115 and snake venom\u2011simulated peptides, delivering stable and low\u2011irritation raw materials for cosmetic manufacturers worldwide.<\/p>\n

The product catalogue also includes other mainstream therapeutic peptide APIs such as tirzepatide, liraglutide and linaclotide. All these goods are produced under unified cGMP quality management framework.<\/p>\n

Core Competitive Strengths as a GMP peptide manufacturer<\/p>\n

First, self\u2011developed synthesis technology for long\u2011chain peptides. Combined solid\u2011liquid phase synthesis techniques reduce side reactions and improve overall yield, solving common purification obstacles faced by complex GLP\u20111 peptide production.<\/p>\n

Second, full\u2011set global compliance qualifications. ISO9001 certification, national pharmaceutical production permit, high\u2011tech enterprise credential, EU API export documents and US DMF records help clients complete overseas product registration smoothly.<\/p>\n

Third, end\u2011to\u2011end technical support. Services span early\u2011stage peptide sequence design, process optimization, stability assessment, mass production, packaging and cold\u2011chain logistics. Clients can obtain full\u2011range support without cooperating with multiple third\u2011party vendors.<\/p>\n

Fourth, global customer service capability. The enterprise takes part in international pharmaceutical exhibitions regularly, and maintains stable long\u2011term partnerships with purchasers from Europe, North America, Southeast Asia and Latin America.<\/p>\n

Get Samples and Quotation<\/p>\n

If you are sourcing high\u2011quality Semaglutide CAS NO: 910463\u201168\u20112, GLP\u20111 related raw materials or seeking reliable peptide processing solutions, feel free to contact Hangzhou Thinheal Pharma\u2011Tech. You can apply for free sample evaluation and obtain customized quotation according to your actual order volume.<\/p>\n

The company sticks to the principle of professionalism and integrity, and keeps supplying cost\u2011effective standardized peptide raw materials and technical services for global partners, pushing forward the innovative development of global peptide pharmaceutical industry.<\/p>\n

About Us<\/strong><\/p>\n

Hangzhou Thinheal Pharma-Tech Co., Ltd. was established in 2019. It is a biopharmaceutical company that combines independent R&D, production, sales and customized research and development and production of peptide products. The core management team is composed of professionals with a pharmaceutical background and nearly 20 years of management experience in the peptide industry.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Hangzhou ThinHeal Pharma-Tech Co., Ltd<\/a>
Contact Person:<\/strong> Media Relations
Email:<\/strong> Send Email<\/a>
Country:<\/strong> China
Website:<\/strong> https:\/\/www.thinhealpeptide.com\/<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Hangzhou, Zhejiang, China – August 26, 2026 – In the booming global metabolic drug market, GLP\u20111 peptide drugs have become core therapeutic products for type 2 diabetes and Weight Management. Among<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/547118"}],"collection":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/comments?post=547118"}],"version-history":[{"count":0,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/posts\/547118\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/media?parent=547118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/categories?post=547118"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.northcarolinaheadlines.com\/news\/wp-json\/wp\/v2\/tags?post=547118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}